Bright Minds Biosciences Inc
DRUG
Company Profile
Business description
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Contact
19 Vestry Street
New YorkNY10013
USAT: +1 647 865-8622
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2025
Employees
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,890.80 | 74.40 | 0.84% |
| CAC 40 | 7,799.57 | 77.48 | 1.00% |
| DAX 40 | 24,272.97 | 263.59 | 1.10% |
| Dow JONES (US) | 44,316.64 | 61.86 | 0.14% |
| FTSE 100 | 8,968.69 | 42.14 | 0.47% |
| HKSE | 24,498.95 | 18.81 | -0.08% |
| NASDAQ | 20,828.83 | 98.34 | 0.47% |
| Nikkei 225 | 39,901.19 | 237.79 | 0.60% |
| NZX 50 Index | 12,905.41 | 150.82 | 1.18% |
| S&P 500 | 6,276.30 | 12.60 | 0.20% |
| S&P/ASX 200 | 8,639.00 | 77.20 | 0.90% |
| SSE Composite Index | 3,516.83 | 13.05 | 0.37% |